A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety in Subjects With Type 1 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Basal and Prandial Insulin Over a 52-Week Treatment Period and a 4-Week Follow Up
A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety in Subjects With Type 1 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Basal and Prandial Insulin Over a 52-Week Treatment Period and a 4-Week Follow Up
To determine the safety and efficacy of inhaled insulin in the treatment of type 1 diabetes
Inclusion Criteria:
Exclusion Criteria:
Minneapolis, Minnesota 55455, United States
Maringa Parana, 87020-900, Brazil
Mexico City, Durango 06700, Mexico
Krakow, POL 31 501, Poland
Bialystok, 15-950, Poland
Lodz, 90-153, Poland
Moscow, RUS 105229, Russia
Moscow, RUS 111399, Russia
Moscow, RUS 119435, Russia
Saint Petersburg, RUS 193012, Russia
Seville, 41071, Spain